SCHEMBL3250370

SCHEMBL3250370

Clc1ncnc2nc(SCc3ccccc3)[nH]c12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.71
NPSR1 Q6W5P4 2/20 0.55
ALDH1A1 P00352 1/20 0.55
TP53 P04637 2/20 0.53
CTSB P07858 3/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.47
CDC7 O00311 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
TOP2A P11388 2/20 0.46
XDH P47989 1/20 0.45
MAOB P27338 1/20 0.45
CXCR2 P25025 1/20 0.44
MAPT P10636 2/20 0.44
SCN9A Q15858 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257038 0.83 LMNA (0.71) LMNANPSR1ALDH1A1TP53NPC1
SCHEMBL3250366 0.82 LMNA (0.58) LMNANPSR1ALDH1A1TP53CTSB
SCHEMBL11356169 0.73 TP53 (0.66) LMNANPSR1ALDH1A1TP53NPC1
Hydrochloric Acid SCHEMBL8056445 0.73 RAB9A (0.55) LMNANPSR1ALDH1A1TP53CTSB
SCHEMBL7005149 0.72 LMNA (0.50) LMNANPSR1TP53CTSBNPC1
SCHEMBL9426904 0.72 HSD17B10 (0.50) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3757591 0.71 CYP1A2 (0.68) LMNAALDH1A1TP53NPC1RAB9A
SCHEMBL29634267 0.71 HTT (0.74) LMNANPSR1ALDH1A1SMN1; SMN2HPGD
SCHEMBL783654 0.70 PI4KA (0.67) ALDH1A1XDH
SCHEMBL3257036 0.69 LMNA (0.56) LMNANPSR1ALDH1A1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896063-B9 Method for the selection of genetically transformed cells and compounds for use in the method SYNGENTA PARTICIPATIONS AG (CH) 2010-05-26 EP disclosed
EP-0896063-B1 Method for the selection of genetically transformed cells and compounds for use in the method SYNGENTA PARTICIPATIONS AG (CH) 2009-09-23 EP disclosed
EP-0601092-B2 METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD SYNGENTA PARTICIPATIONS AG (CH) 2006-11-15 EP disclosed
US-5994629-A Positive selection NOVARTIS AG (CH) 1999-11-30 US disclosed
EP-0601092-B1 METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD NOVARTIS AG (CH) 1999-07-07 EP disclosed
EP-0896063-A2 Method for the selection of genetically transformed cells and compounds for use in the method Novartis AG (CH) 1999-02-10 EP disclosed
EP-0601092-A1 METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD Novartis AG (CH) 1994-06-15 EP disclosed
WO-1993005163-A1 METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD SANDOZ LTD. (CH) 1993-03-18 WO disclosed
EP-0530129-A1 Method for the selection of genetically transformed cells and compounds for use in the method SANDOZ LTD. (CH) 1993-03-03 EP disclosed